DNA icon

Hereditary Breast and Ovarian Cancer via the RAD51D Gene

Summary and Pricing

Test Method

Sequencing and CNV Detection via NextGen Sequencing using PG-Select Capture Probes
Test Code Test Copy GenesTest CPT Code Gene CPT Codes Copy CPT Codes Base Price
7517 RAD51D 81479 81479,81479 $540 Order Options and Pricing
Test Code Test Copy Genes Test CPT Code Gene CPT Codes Copy CPT Code Base Price
7517RAD51D81479 81479,81479 $540 Order Options and Pricing

Pricing Comments

This test is also offered via our exome backbone with CNV detection (click here). The exome-based test may be higher priced, but permits reflex to the entire exome or to any other set of clinically relevant genes.

An additional 25% charge will be applied to STAT orders. STAT orders are prioritized throughout the testing process.

Turnaround Time

18 days on average for standard orders or 13 days on average for STAT orders.

Please note: Once the testing process begins, an Estimated Report Date (ERD) range will be displayed in the portal. This is the most accurate prediction of when your report will be complete and may differ from the average TAT published on our website. About 85% of our tests will be reported within or before the ERD range. We will notify you of significant delays or holds which will impact the ERD. Learn more about turnaround times here.

Targeted Testing

For ordering sequencing of targeted known variants, go to our Targeted Variants page.

EMAIL CONTACTS

Genetic Counselors

Geneticist

  • Hannah Cox, PhD

Clinical Features and Genetics

Clinical Features

Hereditary breast and ovarian cancer (HBOC) syndrome is disorder that is mainly associated with tumors of the breasts and ovaries. Other malignancies in HBOC families can include melanoma, pancreatic and prostate cancer. In comparison to sporadic breast and ovarian cancers, HBOC syndrome tends to occur at an earlier age (i.e. < 50 years), tumors often occur bilaterally, consist of multiple affected family members, including males with breast cancer, and occurs with a higher predisposition in specific ethnicities, such as the Ashkenazi Jewish population (Petrucelli et al. 2011; Pruthi et al. 2010). Identifying individuals with a high risk for developing HBOC may allow for early detection of tumor formation and allow for prophylactic mastectomy and/or oophorectomy or other treatments (Smith 2012). Breast and ovarian cancers can show a familial inheritance due to shared environment or inherited genes of low penetrance, which confer a moderate risk (Berliner et al. 2012). In addition, approximately 5-10% of breast and 10-15% of ovarian cancer cases are the result of genetic predisposition due to gene specific mutations that significantly increase an individual's risk of developing these cancers (Marchina et al. 2010). HBOC syndrome is mainly due to mutations in the BRCA1 and BRCA2 genes, however, pathogenic variants have also been found in other genes.

Genetics

HBOC is inherited in an autosomal dominant manner and presents with incomplete penetrance. The DNA repair protein homolog 4, encoded by the RAD51D gene, is involved in homologous recombinational DNA repair along with RAD51 paralogs (Gutiérrez-Enríquez et al. 2013). RAD51D pathogenic variants have been found to confer an increased risk of breast and ovarian cancer, but are often found at a higher frequency in families with ovarian cancer (Gutiérrez-Enríquez et al. 2013; Loveday et al. 2011; Osher et al. 2012). The most prominent RAD51D causative mutations are missense and nonsense variants, but other sequence changes such as splice site, small insertions and deletions have also been reported (Human Gene Mutation Database).

Clinical Sensitivity - Sequencing with CNV PG-Select

Clinical sensitivity is low because HBOC has multiple underlying causes including environment and genetics. RAD51D pathogenic variants have only been reported in a small minority of hereditary breast and ovarian cases (Gutiérrez-Enríquez et al. 2013). To our knowledge, large deletions/duplications have not been reported and thus the clinical sensitivity of pathogenic copy number variants is unknown.

Testing Strategy

This test provides full coverage of all coding exons of the RAD51D gene, plus ~10 bases of flanking noncoding DNA. We define full coverage as >20X NGS reads or Sanger sequencing.

Indications for Test

Individuals with a clinical presentation or family of Hereditary Breast and Ovarian Cancer and have tested negative for BRCA1 and BRCA2 gene mutations. Males with breast cancer, and individuals with an Ashkenazi descent with a concern for HBOC should also be tested. Earlier detection of clinical abnormalities may lead to earlier treatment and better outcomes. Similar to BRCA mutation testing, this is a predictive test and provides only information regarding the likelihood of breast and/or ovarian cancer. This test is specifically designed for heritable germline mutations and is not appropriate for the detection of somatic mutations in tumor tissue.

Gene

Official Gene Symbol OMIM ID
RAD51D 602954
Inheritance Abbreviation
Autosomal Dominant AD
Autosomal Recessive AR
X-Linked XL
Mitochondrial MT

Disease

Name Inheritance OMIM ID
Breast-Ovarian Cancer, Familial 4 614291

Related Tests

Name
Hereditary Breast and Ovarian Cancer - High Risk and Lynch Syndrome Panel
Hereditary Breast and Ovarian Cancer via the BARD1 Gene
Hereditary Breast and Ovarian Cancer via the RAD50 Gene
Hereditary Breast Cancer via the CHEK2 Gene

Citations

  • Berliner JL, Fay AM, Cummings SA, Burnett B, Tillmanns T. 2012. NSGC Practice Guideline: Risk Assessment and Genetic Counseling for Hereditary Breast and Ovarian Cancer. Journal of Genetic Counseling 22: 155–163. PubMed ID: 23188549
  • Gutiérrez-Enríquez S, Bonache S, Ruíz de Garibay G, Osorio A, Santamariña M, Ramón y Cajal T, Esteban-Cardeñosa E, Tenés A, Yanowsky K, Barroso A, Montalban G, Blanco A, et al. 2013. About 1% of the breast and ovarian Spanish families testing negative for BRCA1 and BRCA2 are carriers of RAD51D pathogenic variants: RAD51D germline mutations in breast and ovarian Spanish families. International Journal of Cancer n/a–n/a. PubMed ID: 24130102
  • Human Gene Mutation Database (Bio-base).
  • Loveday C, Turnbull C, Ramsay E, Hughes D, Ruark E, Frankum JR, Bowden G, Kalmyrzaev B, Warren-Perry M, Snape K, Adlard JW, Barwell J, et al. 2011. Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nature Genetics 43: 879–882. PubMed ID: 21822267
  • Marchina E, Fontana MG, Speziani M, Salvi A, Ricca G, Di Lorenzo D, Gervasi M, Caimi L, Barlati S. 2010. BRCA1 and BRCA2 genetic test in high risk patients and families: counselling and management. Oncology Reports 24: 1661-1667. PubMed ID: 21042765
  • Osher DJ, Leeneer K De, Michils G, Hamel N, Tomiak E, Poppe B, Leunen K, Legius E, Shuen A, Smith E, Arseneau J, Tonin P, et al. 2012. Mutation analysis of RAD51D in non-BRCA1/2 ovarian and breast cancer families. British Journal of Cancer 106: 1460–1463. PubMed ID: 22415235
  • Petrucelli N, Daly MB, Feldman GL. BRCA1 and BRCA2 Hereditary Breast and Ovarian Cancer. 1998 Sep 4 [Updated 2011 Jan 20]. In: Pagon RA, Adam MP, Bird TD, et al., editors. GeneReviews™ [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2013. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1247/ PubMed ID: 20301425
  • Pruthi S, Gostout BS, Lindor NM. 2010. Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer. Mayo Clinic Proceedings 85: 1111–1120. PubMed ID: 21123638
  • Smith EC. 2012. An Overview of Hereditary Breast and Ovarian Cancer Syndrome. Journal of Midwifery & Women’s Health 57: 577–584. PubMed ID: 23050669

Ordering/Specimens

Ordering Options

We offer several options when ordering sequencing tests. For more information on these options, see our Ordering Instructions page. To view available options, click on the Order Options button within the test description.

myPrevent - Online Ordering

  • The test can be added to your online orders in the Summary and Pricing section.
  • Once the test has been added log in to myPrevent to fill out an online requisition form.
  • PGnome sequencing panels can be ordered via the myPrevent portal only at this time.

Requisition Form

  • A completed requisition form must accompany all specimens.
  • Billing information along with specimen and shipping instructions are within the requisition form.
  • All testing must be ordered by a qualified healthcare provider.

For Requisition Forms, visit our Forms page


Specimen Types

Specimen Requirements and Shipping Details

loading Loading... ×

ORDER OPTIONS

View Ordering Instructions

1) Select Test Method (Backbone)


1) Select Test Type


2) Select Additional Test Options

STAT and Prenatal Test Options are not available with Patient Plus.

No Additional Test Options are available for this test.

Note: acceptable specimen types are whole blood and DNA from whole blood only.
Total Price: $
×
Copy Text to Clipboard
×